Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Events

08 Dec 2026 - 10 Dec 2026
25 Jan 2027 - 28 Jan 2027

Novel Assay Allows Individualized Chemotherapy Management Monitoring

By HospiMedica staff writers
Posted on 01 Jul 2008
The 5-FU Personalized Chemotherapy Management (PCM) assay, intended for use on the Olympus AU400 clinical chemistry analyzer, allows oncologists who prescribe 5-fluorouracil (5-FU) continuous infusion regimens (alone or in combination for colorectal, stomach, breast, and pancreatic cancers) to control and fine-tune individualized dosing. More...
Recent results from a Phase III randomized study compared colorectal cancer patients who were dosed with 5-FU based on body surface area (BSA, the current standard dosing method) with patients whose dose was adjusted based on the actual concentration of 5-FU in blood plasma. The study results showed that response rates among monitored patients doubled; two-year overall survival improved by 48%; and toxic side effects were significantly lower. Additionally, only 25% of BSA dosed patients were found to be in the target range to receive the optimal therapeutic benefit; 58% of patients were found to be under-dosed and had doses adjusted upward, while 17% were found to be over-dosed, increasing the risk of severe side effects. The study was published in the May 2008 issue of the Journal of Clinical Oncology.

"The availability of the 5-FU PCM assay will give oncologists in the European Union a powerful, cost-effective tool in the battle against colorectal cancer,” said lead author Erick Gamelin, M.D., Ph.D., director of the Paul Papin Cancer Center (Angers, France). "Our Phase III study demonstrates that the majority of patients are either over-dosed or in most cases, under-dosed. Personalized 5-FU dosing allows us to substantially reduce severe toxicity while improving patient quality of life and treatment outcomes.”

The 5-FU Personalized Chemotherapy Management assay system is a product of Saladax Biomedical (Bethlehem, PA, USA), and has received CE marking registration in the European Union (EU).

"Until now, a simple, rapid, and cost-effective 5-FU measurement tool that can be easily integrated into day-to-day practice has not been readily available. As a result, colorectal cancer patients receive chemotherapy based on their height and weight, with no monitoring system in place to allow oncologists to correlate dose with clinical patient response on an ongoing basis,” said Salvatore Salamone, Ph.D., CEO of Saladax Biomedical. "Access to this simple blood test will arm oncologists with the ability to individualize 5-FU dosing to ensure patients receive the optimal benefit from their treatment.”

Colorectal cancer is a worldwide public health problem, with more than 940,000 new cases diagnosed each year, resulting in approximately 500,000 deaths annually, according to data from the World Health Organization (WHO, Geneva, Switzerland). In the United States, colorectal cancer is the third leading cause of cancer mortality, and in 2008, nearly 50,000 deaths will be attributed to this disease. Data from industrialized countries demonstrate that incidence rates are strongly correlated with age, rising three-fold between the ages of 60 and 80 years.


Related Links:
Paul Papin Cancer Center
Saladax Biomedical

Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Hand-held Hemoglobin Analyzer
DiaSpect Tm
Hybrid Arch Device
Neo EDE
Medical-Grade Display
HL2316SHTB
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: A view inside the custom virtual reality environment used in the study: a calm room with a teddy bear, soft colors and large windows looking out over the sea. (Image Credit: Walaa S. Abu Rukbah et al., Virginia Commonwealth University; CC-BY 4.0, https://creativecommons.org/licenses/by/4.0/)

Virtual Reality Program May Reduce Anxiety Before Pediatric Surgery

Presurgery anxiety affects an estimated 50% to 75% of children undergoing surgery and can complicate anesthesia induction, increase postoperative pain, and prolong recovery. Sedation is often used to manage... Read more

Medical Imaging

view channel
Image Credit: Adobe Stock

Lung Ultrasound Predicts Progression of Interstitial Lung Abnormalities in Rheumatoid Arthritis

Interstitial lung abnormalities are a pulmonary concern in patients with rheumatoid arthritis, requiring monitoring to detect disease progression. However, tracking these changes often involves repeated... Read more

Point of Care

view channel
Image: Jessica Ramella-Roman, professor of biomedical engineering at Florida International University, holding the PPRIM (Portable Preterm Imaging) device designed to detect early signs of preterm labor risk. (Photo courtesy of Florida International University)

Handheld Imaging Device May Help Identify Preterm Birth Risk Earlier

Preterm birth, defined as delivery before 37 weeks of pregnancy, can lead to serious neonatal complications, including neurological, developmental, and respiratory problems. However, identifying pregnancies... Read more

Business

view channel
Image: Stryker has acquired ZuriMED, adding the FiberLocker System, a rotator cuff augmentation technology designed to strengthen repairs, to its Sports Medicine portfolio. (Photo courtesy of ZuriMED)

Stryker Completes Acquisition to Broaden Shoulder Surgery Offerings

Stryker (Portage, MI, USA) has completed its acquisition of ZuriMED (Zurich, Switzerland), a privately held developer of the FiberLocker System, expanding its Sports Medicine portfolio with a commercialized... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.